Trefoil Peptides in Lung Diseases

Overview

The study focuses on trefoil family factor (TFF) peptides in sputum in lung diseases. The investigators hypothesize that TFF peptides are upregulated in lung diseases characterized by mucus hypersecretion.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 2010

Arms, Groups and Cohorts

  • COPD
    • Chronic obstructive pulmonary disease
  • Asthma
  • Healthy controls

Clinical Trial Outcome Measures

Primary Measures

  • TFF in sputum
    • Time Frame: Monthly

Participating in This Clinical Trial

Inclusion Criteria

  • Age 18 years or older
  • Informed consent

Exclusion Criteria

  • Upper and lower airway infection 2 weeks prior to visit 1

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Bispebjerg Hospital
  • Provider of Information About this Clinical Study
    • Thomas K. Lund (MD PhD) & Lars Pedersen (MD PhD), Respiratory and Allergy Research Unit, Department of Respiratory Medicine, Bispebjerg Hospital, Copenhagen, Denmark
  • Overall Official(s)
    • Thomas K Lund, MD PhD, Principal Investigator, Respiratory and Allergy Research Unit
  • Overall Contact(s)
    • Thomas K Lund, MD PhD, (+45) 35 31 30 69, tclund@dadlnet.dk

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.